| scholarly article | Q13442814 |
| P50 | author | Susan G Dorsey | Q60843043 |
| Jennifer Le-Rademacher | Q75026031 | ||
| P2093 | author name string | Alexej Abyzov | |
| Jeff Sloan | |||
| Rui Qin | |||
| Neil K Aaronson | |||
| Charles L Loprinzi | |||
| Deirdre R Pachman | |||
| Kathryn J Ruddy | |||
| Andreas S Beutler | |||
| Ellen M Lavoie Smith | |||
| Michaela S Banck | |||
| Rahul Kanwar | |||
| Drew Seisler | |||
| P2860 | cites work | Chemotherapy-induced peripheral neuropathy: prevention and treatment | Q37911252 |
| Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review | Q38208769 | ||
| Challenges in the conduct of research: chemotherapy-induced peripheral neuropathy | Q38230429 | ||
| Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study | Q40247128 | ||
| Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial | Q40757672 | ||
| Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? | Q42512760 | ||
| Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. | Q46069967 | ||
| Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? | Q52895881 | ||
| Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. | Q52905253 | ||
| The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 | Q81776925 | ||
| Chemotherapy-induced peripheral neuropathy in pediatric cancer patients | Q84234849 | ||
| North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study | Q33717608 | ||
| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline | Q34415239 | ||
| A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. | Q34619839 | ||
| Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1 | Q34866427 | ||
| Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire | Q35248222 | ||
| The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial | Q35898610 | ||
| Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients | Q36219570 | ||
| The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings | Q36551631 | ||
| Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Q36872264 | ||
| Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy | Q36977059 | ||
| MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy | Q37082272 | ||
| Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin | Q37404101 | ||
| Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). | Q37662241 | ||
| P921 | main subject | peripheral neuropathy | Q945238 |
| P577 | publication date | 2017-06-20 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials |
| Q61797229 | Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy |
| Q92865754 | Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review |
| Q55031561 | Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients. |
| Q90083508 | Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study |
| Q52691988 | Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. |
| Q90467662 | Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study |
| Q57135103 | Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy |
| Q64120952 | Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A15140 |
| Q92335764 | The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy |
| Q47928562 | The past and future of 'reported outcomes' in studies on chemotherapy neuropathy |
Search more.